Organisation paid for research Program year 2025 Source: CMS Open Payments

Medvadis Research Corp LLC

Neither a doctor nor a teaching hospital

Research payments

$19,221,530

198 payments

Through program year 2025, Medvadis Research Corp LLC is reported as receiving $19,221,530 in research payments, across 198 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$3,774,855	31
2024	Research	$3,812,533	35
2023	Research	$5,343,046	42
2022	Research	$3,269,514	30
2021	Research	$2,590,008	34
2020	Research	$431,573	26

Breakdown

Who paid Research payments · program years 2020–2025

Eli Lilly and Company $18,960,223 165 payments
H. Lundbeck A S $174,628 23 payments
GlaxoSmithKline, LLC. $83,881 9 payments
Eli Lilly Export S.A. Puerto Rico Branch $2,799 1 payment

Studies the money was for Research payments · program years 2020–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $2,203,047 8 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $1,586,328 2 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $1,295,758 6 payments
Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $1,223,269 9 payments
A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $950,356 2 payments
A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $936,891 2 payments
A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $849,396 4 payments
A Study of Retatrutide (Ly3437943) Once Weekly in Participants Who Have Obesity Or Overweight and Osteoarthritis of the Knee (Triumph-4) $776,513 4 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $659,393 2 payments
Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $588,953 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.